STAT3 silencing enhances the efficacy of the HSV.tk suicide gene in gastrointestinal cancer therapy

Clinical and Experimental Metastasis

Volumn 29, Issue 4, 2012, Pages 359-369

  Ahn, Ye Hyeon ^b,c   Yi, Hwajung ^b   Shin, Ji Young ^b   Lee, Kang Duck ^b   Shin, Seung Pil ^b   Lee, Sang Jin ^b   Song, Jaewhan ^c   Chun, Kyung Hee ^a  

^a Yonsei University College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

Anti tumor immune response; Gastrointestinal cancer; Gene therapy; STAT3; Thymidine kinase

Indexed keywords

GANCICLOVIR; SITIMAGENE CERADENOVEC; SMALL INTERFERING RNA; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LENTIVIRINAE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STOMACH CANCER; SUICIDE GENE THERAPY; T LYMPHOCYTE; XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; GASTROINTESTINAL NEOPLASMS; GENE SILENCING; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; HUMANS; MICE; SIMPLEXVIRUS; STAT3 TRANSCRIPTION FACTOR; THYMIDINE KINASE; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862824887     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9458-4     Document Type: Article

References (29)

1. Gao H, Ward PA (2007) STAT3 and suppressor of cytokine signaling 3: potential targets in lung inflammatory responses. Expert Opin Ther Targets 11:869-880 (Pubitemid 47061314)
2. Brantley EC, Benveniste EN (2008) Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res 6:675-684
3. Jackson CB, Giraud AS (2009) STAT3 as a prognostic marker in human gastric cancer. J Gastroenterol Hepatol 24:505-507
4. Turkson J, Jove R (2000) STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19:6613-6626 (Pubitemid 32197700)
5. Oka M, Sakaguchi M, Okada T, Nagai H, Ozaki M, et al. (2010) Signal transducer and activator of transcription 3 upregulates interleukin-8 expression at the level of transcription in human melanoma cells. Exp Dermatol 19(8):e50-5
6. Fitzgerald JS, Busch S, Wengenmayer T, Foerster K, de la Motte T et al (2005) Signal transduction in trophoblast invasion. Chem Immunol Allergy 88:181-199 (Pubitemid 43094385)
7. Huang S (2007) Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res 13:1362-1366
8. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A et al (2006) Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 15:1445-1451
9. Ito N, Eto M, Nakamura E, Takahashi A, Tsukamoto T et al (2007) STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol 25:2785-2791 (Pubitemid 47123187)
10. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S et al (2005) Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11:1314-1321 (Pubitemid 41752912)
11. Kortylewski M, Yu H (2007) Stat3 as a potential target for cancer immunotherapy. J Immunother 30:131-139 (Pubitemid 46667794)
12. Kortylewski M, Yu H (2008) Role of Stat3 in suppressing antitumor immunity. Curr Opin Immunol 20:228-233
13. Gariboldi MB, Ravizza R, Molteni R, Osella D, Gabano E et al (2007) Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett 258:181-188 (Pubitemid 350101017)
14. Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H et al (2007) Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448:1058-1062 (Pubitemid 47345590)
15. Lewis HD, Winter A, Murphy TF, Tripathi S, Pandey VN et al (2008) STAT3 inhibition in prostate and pancreatic cancer lines by STAT3 binding sequence oligonucleotides: differential activity between 50 and 30 ends. Mol Cancer Ther 7:1543-1550
16. Li WC, Ye SL, Sun RX, Liu YK, Tang ZY et al (2006) Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res 12:7140-7148
17. Kim SJ, Choi IJ, Cheong TC, Lee SJ, Lotan R et al (2010) Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology 138(1035-1045):e1031- e1032
18. Cheong TC, Shin JY, Chun KH (2010) Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents. Cancer Sci 101: 94-102
19. Kim SJ, Oh JS, Shin JY, Lee KD, Sung KW et al (2011) Development of microRNA-145 for therapeutic application in breast cancer. J Control Release 155:427-434
20. Park JS, Kim HS, Park MY, Kim CH, Chung YJ et al (2010) Topoisomerase II alpha as a universal tumor antigen: antitumor immunity in murine tumor models and H-2K(b)-restricted T cell epitope. Cancer Immunol Immunother 59:747-757
21. Arici DS, Tuncer E, Ozer H, Simek G, Koyuncu A (2009) Expression of retinoblastoma and cyclin D1 in gastric carcinoma. Neoplasma 56:63-67
22. Zushi S, Shinomura Y, Kiyohara T, Miyazaki Y, Kondo S et al (1998) STAT3 mediates the survival signal in oncogenic rastransfected intestinal epithelial cells. Int J Cancer 78:326-330 (Pubitemid 28445370)
23. Lau CK, Yang ZF, Lam SP, Lam CT, Ngai P et al (2007) Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. Cancer Biol Ther 6:1900-1907 (Pubitemid 351590402)
24. Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M et al (1999) Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 59:5059-5063 (Pubitemid 29503958)
25. Niu G, Wright KL, Huang M, Song L, Haura E et al (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21:2000-2008 (Pubitemid 34270888)
26. Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C et al (1997) Generation of an anti-tumour immune response in a nonimmunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 71:267-274 (Pubitemid 27253001)
27. Mizuguchi H, Hayakawa T (2002) Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase. Cancer Gene Ther 9:236-242 (Pubitemid 34205497)
28. Suzuki T, Sakurai F, Nakamura S, Kouyama E, Kawabata K et al (2008) miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy. Mol Ther 16:1719-1726
29. Littlejohn JE, Cao X, Miller SD, Ozvaran MK, Jupiter D et al (2008) Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts. Int J Cancer 123:202-208 (Pubitemid 351705210)